These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27261537

  • 1. Pharmacogenetics of dabigatran etexilate interindividual variability.
    Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M.
    Thromb Res; 2016 Aug; 144():1-5. PubMed ID: 27261537
    [Abstract] [Full Text] [Related]

  • 2. The Distribution of the Genotypes of ABCB1 and CES1 Polymorphisms in Kazakhstani Patients with Atrial Fibrillation Treated with DOAC.
    Abdrakhmanov A, Akilzhanova A, Shaimerdinova A, Zhalbinova M, Tuyakova G, Abildinova S, Albayev R, Ainabekova B, Chinybayeva A, Suleimen Z, Bekbossynova M.
    Genes (Basel); 2023 May 29; 14(6):. PubMed ID: 37372371
    [Abstract] [Full Text] [Related]

  • 3. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
    Sychev D, Skripka A, Ryzhikova K, Bochkov P, Shevchenko R, Krupenin P, Ivashchenko D, Kogay V, Listratov A, Krainyaya A, Gurinovich O, Sokolova A, Napalkov D, Fomin V.
    Drug Metab Pers Ther; 2020 Mar 05; 35(1):. PubMed ID: 32134727
    [Abstract] [Full Text] [Related]

  • 4. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
    Ji Q, Zhang C, Xu Q, Wang Z, Li X, Lv Q.
    Br J Clin Pharmacol; 2021 May 05; 87(5):2247-2255. PubMed ID: 33179295
    [Abstract] [Full Text] [Related]

  • 5. The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients.
    Olšerová A, Janský P, Magerová H, Šrámková T, Kešnerová P, Kmetonyová S, Šulc V, Halmová H, Šrámek M, Šarbochová I, Paulasová-Schwabová J, Benešová K, Macek J, Maťoška V, Tomek A.
    Am J Ther; 2021 May 05; 31(4):e362-e371. PubMed ID: 38525959
    [Abstract] [Full Text] [Related]

  • 6. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
    Zhu Z, Qian C, Su C, Tao H, Mao J, Guo Z, Zhu X, Pan J.
    BMC Cardiovasc Disord; 2022 Nov 11; 22(1):481. PubMed ID: 36368930
    [Abstract] [Full Text] [Related]

  • 7. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ.
    Biochem Pharmacol; 2016 Nov 01; 119():76-84. PubMed ID: 27614009
    [Abstract] [Full Text] [Related]

  • 8. Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation.
    Cumitini L, Renda G, Giordano M, Rolla R, Shail T, Sacchetti S, Iezzi L, Giacomini L, Zanotti V, Auciello R, Angilletta I, Foglietta M, Zucchelli M, Antonucci I, Stuppia L, Gallina S, Dianzani U, Patti G.
    J Clin Med; 2024 Apr 26; 13(9):. PubMed ID: 38731074
    [Abstract] [Full Text] [Related]

  • 9. Genetic determinants of dabigatran plasma levels and their relation to bleeding.
    Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L.
    Circulation; 2013 Apr 02; 127(13):1404-12. PubMed ID: 23467860
    [Abstract] [Full Text] [Related]

  • 10. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.
    Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T.
    Pharmgenomics Pers Med; 2018 Apr 02; 11():127-137. PubMed ID: 30100750
    [Abstract] [Full Text] [Related]

  • 11. Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population.
    Abdrakhmanov A, Zholdybayeva E, Shaimerdinova A, Kulmambetova G, Abildinova S, Albayev R, Tuyakova G, Rib E, Suleimen Z, Abdrakhmanova Z, Bekbossynova M.
    Caspian J Intern Med; 2024 Apr 02; 15(3):499-508. PubMed ID: 39011438
    [Abstract] [Full Text] [Related]

  • 12. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
    Zubiaur P, Saiz-Rodríguez M, Ochoa D, Navares-Gómez M, Mejía G, Román M, Koller D, Soria-Chacartegui P, Almenara S, Abad-Santos F.
    Adv Ther; 2020 Aug 02; 37(8):3537-3550. PubMed ID: 32564268
    [Abstract] [Full Text] [Related]

  • 13. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects.
    Liu Y, Yang C, Qi W, Pei Z, Xue W, Zhu H, Dong M, Guo Y, Cong D, Wang F.
    Pharmgenomics Pers Med; 2021 Aug 02; 14():477-485. PubMed ID: 33935512
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
    Šinigoj P, Malmström RE, Vene N, Rönquist-Nii Y, Božič-Mijovski M, Pohanka A, Antovic JP, Mavri A.
    Basic Clin Pharmacol Toxicol; 2015 Nov 02; 117(5):323-9. PubMed ID: 25981948
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation.
    Tomita H, Araki T, Kadokami T, Yamada S, Nakamura R, Imamura Y, Fukuyama T, Nagano D, Hashimoto T, Uematsu A, Hosokawa K, Yamamoto K, Ueda S, Ando S, ATTACK-DB research group.
    Thromb Res; 2016 Sep 02; 145():100-6. PubMed ID: 27526389
    [Abstract] [Full Text] [Related]

  • 17. A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
    Wang H, Zhou Y, Rong G, Lu L, Zhang J.
    Blood Coagul Fibrinolysis; 2016 Jul 02; 27(5):563-7. PubMed ID: 26881855
    [Abstract] [Full Text] [Related]

  • 18. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
    Taune V, Wallén H, Ågren A, Gryfelt G, Sjövik C, Wintler AM, Malmström RE, Wikman A, Skeppholm M.
    Thromb Res; 2017 May 02; 153():76-82. PubMed ID: 28347811
    [Abstract] [Full Text] [Related]

  • 19. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation.
    Boonen K, Schmitz E, Rozestraten F, van den Heuvel D, Brunsveld L, van der Voort P, van de Kerkhof D.
    Clin Chem Lab Med; 2017 Oct 26; 55(12):2002-2009. PubMed ID: 28328523
    [Abstract] [Full Text] [Related]

  • 20. Real-world variability in dabigatran levels in patients with atrial fibrillation.
    Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis JD, Schulman S, Eikelboom JW.
    J Thromb Haemost; 2015 Mar 26; 13(3):353-9. PubMed ID: 25523236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.